← SynDRA
LB-100
SynDRA canonical compound SYN2077635 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PPP5C |
|---|
| Mechanism of action | protein phosphatase inhibitor |
|---|
| Indication | depression |
|---|
| Disease area | Neurology |
|---|
All known targets
- PPP5C
- PPP2CB
- PPP2CA
- PPP2R1A
Mechanisms of action (all sources)
- PPP2CA INHIBITOR
- Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor
- PPP2CB INHIBITOR
- Serine/threonine protein phosphatase 2A, catalytic subunit, beta isoform inhibitor
- PPP5C INHIBITOR
- Serine/threonine-protein phosphatase 5 inhibitor
- PPP2R1A INHIBITOR
- protein phosphatase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Cross-references
Synonyms
- SCHEMBL26377801
- BDBM50618390
- PD132534
- SCHEMBL12390164
- LB 100
- T4449
- AKOS027338657
- MFCD28167839
- orb1302850
- RefChem:152591
- AC-37584
- UNII-0C1JUU9S0L
- endothall 4-methylpiperazine monoamide
- LB100
- 0C1JUU9S0L
- HQC03253
- SCHEMBL9880148
- DA-74917
- GTPL11105
- EMPM
- TS-09026
- DTXCID501563640
- BRD-A73709786-001-02-1
- TS-08113
- SCHEMBL2832350
- s7537
- CCG-267133
- RefChem:911017
- DA-69238
- LB-100?
- orb1306576
- AC-32634
- AKOS003795667
- SB17253
- HY-W328402
- EX-A2210
- F765414
- AK-968/40946742
- CS-0439967
Look up LB-100 in the interactive SynDRA portal →